Protagonist Therapeutics
PTGX
PTGX
166 hedge funds and large institutions have $1.57B invested in Protagonist Therapeutics in 2023 Q2 according to their latest regulatory filings, with 44 funds opening new positions, 59 increasing their positions, 48 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
23% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 48
22% more funds holding
Funds holding: 136 → 166 (+30)
4.67% less ownership
Funds ownership: 103.77% → 99.1% (-4.7%)
Holders
166
Holding in Top 10
5
Calls
$49.7M
Puts
$22.8M
Top Buyers
| 1 | +$52.4M | |
| 2 | +$45.8M | |
| 3 | +$31.4M | |
| 4 |
RI
RTW Investments
New York
|
+$22.5M |
| 5 |
Holocene Advisors
New York
|
+$22.2M |
Top Sellers
| 1 | -$34.9M | |
| 2 | -$33.2M | |
| 3 | -$27.4M | |
| 4 |
Millennium Management
New York
|
-$21.3M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$17M |